AN2 Therapeutics (ANTX) stock

Boron-based medicines , market cap $137M

Boron-based medicines for Chagas disease

Market cap $137M

$3.63

+2.25%

As of Monday's close · Live for Pro members at the open

Quality Score

-2

Poor

In its industry

#166of 291

Biotech

Checks firing

2of 14

Trending up

From 52-week high

-49.5%

Below the 200-day

ANTX's Quality Score was unchanged on Mon, Oct 26, at -2.

Follow ANTX's trial news. Pro members can get an alert when AN2 Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when ANTX files news on its trialSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextEnd of 2026“…and safety profile support planned Phase 2 initiation of AN2-502998 in chronic Chagas disease by year-end”Trial start · SEC filing · Aug 11

Cash$79.9M, about 10 quarters (2.5 years) at the last year's spendingOn Jun 30 · the company says “into 2029”

Why is ANTX down?

Down 28% in 3 months, 30% under its 50-day average.

Down more than its industry: the 280 other stocks in it fell a median 13% over the same 3 months.

−2Dilution 48.4% more shares outstanding than a year ago

4 more things pulling ANTX's score down, for Pro members.

Get an alert when ANTX's Quality Score turns up →

Key facts on ANTX

Key facts on ANTX
Holding it back	48.4% more shares than a year ago
Latest filing	10-Q, Aug 11 Filed its quarterly report (10-Q) for the quarter to Jun 30, 2026

6 more reasons behind ANTX's -2, for Pro members.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Cash$79.9M, about 10 quarters (2.5 years) at the last year's spendingOn Jun 30 · the company says “into 2029”

ANTX catalysts

Coming up

After its last 4 reports it closed -3.6% on average, higher 1 of 4 times.

3 more coming up and 2 past catalysts since 2026, with sizes and sources, for Pro members.Get in free →

What's next for ANTX, and how long its cash lasts

Next step the company has named

End of 2026“Positive non-human primate efficacy and favorable Phase 1 clinical pharmacokinetics and safety profile support planned Phase 2 initiation of AN2-502998 in chronic Chagas disease by year-end”Trial start · SEC filing · Aug 11

What it means: when a trial begins, or reaches the stage the company named.

A trial underway: Oral Epetraborole in Adults With Polycythemia VeraPhase 2 · Not yet recruiting · 75 people · main data estimated Apr 2029 · NCT07891533

For Pro members: 4 more milestones and 27 filings.

Cash runway Jun 30 balance sheet

About 10 quarters

$79.9M in cash and investments (as the company counts them), at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “into 2029” (8-K, May 11).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Apr 9, 2026)
At-the-market share sales program (424B5, filed Apr 20, 2026)

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

Director Robin Shane Readnour sold 1,108 shares on Sep 9, under a planned sale. 11 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Eric Easom buys or sells

For Pro members: every trade, and Eric Easom’s 10 filings and quotes.

Get an alert when ANTX files news on its trialSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 15 daysANDA decisionIn 15 days · ANDA decisionNRXPNRX PharmaceuticalsPreservative-free ketamineNRXPNRX Pharmaceuticals · $104MPreservative-free ketamineA generic, under FDA review (GDUFA)
In 27 daysFDA decisionIn 27 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $356MDeramiocelFDA decision due (PDUFA)
In 27 daysFDA decisionIn 27 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $933MMolgramostimFDA decision due (PDUFA)

10 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 168 dates, ranked →

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on ANTX and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

ANTX has 2 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on ANTX, and all 14 on every stock.Get in free →

ANTX RSI today: 32.5, below its 50-day and 200-day averages

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

RSI 1432.5
Above 30, below 50.
MACD (12, 26, 9)Below signal
Crossed below its signal line 12 sessions ago.
50-day average$5.01
The price is 27.5% below it.
200-day average$4.01
The price is 9.5% below it.
50/200 crossGolden cross
The 50-day crossed above the 200-day on Mar 6.
ADX 1432.4
25 or more, with +DI below -DI.
Support$3.21
Swing low from Oct 19, 11.6% below the price.
Resistance$5.00
Swing high from May 14, 37.7% above the price.
52-week high$7.19
From Aug 12, 98.1% above the price.
52-week low$1.00
From Jan 5, 72.5% below the price.
Chart patternNone
No triangle, channel, or wedge in the last year.
Bollinger Bands (20, 2)Inside
The bands run from $2.64 to $5.97.
Volume0.6x
Against its 20-day average, for the time of day.

The deep dive on ANTX

What it does and how it makes money2 findingsFor Pro members2 findings on what ANTX does and how it makes money, for Pro members
Where it stands2 findings1 offering of shares or notes since Apr 2026, $80.0M in all.SEC filing · Apr 20, 2026
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades ANTX, for Pro members

5 more findings on ANTX, each with its source, for Pro membersGet in free →

How ANTX ranks in Biotech

ANTX is #166 of 291 by Quality Score.

How ANTX ranks in Biotech
1	HALOHalozyme Therapeutics	9/14	21
2	AMRXAmneal Pharmaceuticals	9/14	20
3	RIGLRigel Pharmaceuticals	9/14	19
	ANABAnaptysBio		Open for its score
	ANIPANI Pharmaceuticals		Open for its score
	AQSTAquestive Therapeutics		Open for its score
	ARCTArcturus Therapeutics		Open for its score
166	ANTXAN2 Therapeutics	2/14	-2

When does ANTX report earnings, and what happens after?

Expected to report Wed Nov 11, after the close (in 16 days). Expected.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What ANTX reported on Aug 11, 2026

The quarter

The figures are not read from the release yet.

“R&D expenses for the second quarter of 2026 were $6.0 million, compared to $3.2 million for the same period during 2025 due to increased chemistry manufacturing and controls (CMC) expenses, other miscellaneous expenses, consulting and outside services, preclinical and research studies expenses, and clinical trial expenses.”

The filing on EDGAR

Where the sales came from

ANTX's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

“G&A expenses for the second quarter of 2026 were $2.9 million, compared to $4.0 million for the same period in 2025 due to decreased professional and outside services expenses and personnel-related expenses.”

From its results filing (SEC filing · Aug 11)

1 more sentence, for Pro members.

The numbers

Market value: $137M; today

No analyst estimates on Breakaway: every figure here is filed.

The whole report on ANTX: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.Get in free →

-7.6%-9.5%+7.0%

Mar 17May 11Aug 11

Reported	When	Gap	Reaction	5 sessions
Aug 11, 2026After close	After close	+3.8%	+7.0%	+1.7%
May 11, 2026After close	After close	-3.0%	-9.5%	-5.1%
Mar 17, 2026After close	After close	-3.0%	-7.6%	-24.6%

ANTX closed higher after 1 of its last 4 reports.

All 4 reports, and ANTX's Quality Score going into each

ANTX share count over time

48% more shares than a year earlier.

Weighted shares, quarter to Jun 30, 2026, both from one filing

Shares of ANTX outstanding, as filed
Shares outstanding	As of
37.7M	Aug 6, 2026
36M	May 7, 2026
35.9M	Mar 10, 2026
27.4M	Nov 3, 2025

Offerings, shelves, and splits of ANTX, from its filings
From its filings	Filed
Set up an at-the-market program for up to $80M of shares, about 58% of its market value	Apr 20, 2026
Registered shares for a later sale (S-3)	Apr 9, 2026

Who is trading ANTX

ANTX insider trades

One insider sold $25K across 1 filing in the last 6 months. No open-⁠market buys on record. The newest:

SellJoshua M. Eizen$25KInsiderat $4.17 on Jul 8, filed Jul 10

SellJoshua M. EizenInsider$25Kat $4.17 on Jul 8, filed Jul 10

ANTX's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Joshua M. EizenOfficer · 1 trade
Sarah Joanne WilliamsPrincipal Accounting Officer · 1 trade
Cameron C. Trenor IIIChief Medical Officer
Robin Shane ReadnourDirector · 4 trades
Margaret M. FitzPatrickDirector · 1 trade
Gilbert Lynn MarksDirector
Joseph S. ZakrzewskiDirector
Kabeer AzizDirector

One more officer or director files at ANTX. Each page above names the rest.

See insider trades by person

Which ETFs hold ANTX?

In ETFs: ANTX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About AN2 Therapeutics

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.

21 employeesMenlo Park, CAan2therapeutics.com

ANTX's score card

AN2 Therapeutics (ANTX): Quality Score -2, Poor, #166 of 291 in Biotech, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would turn ANTX's score around: 7 things
2 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayJul 10Joshua M. Eizen sold ANTX$25K at $4.17, filed Jul 10

Alerts are optional.

See ANTX's 14 chart checks

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Straight Answers

As of Oct 26, 2026: ANTX's Quality Score is -2 (Poor), #166 of 291 in Biotech. Insiders sold $25K in the last 6 months (Form 4).

Is ANTX a good stock to buy? What its Quality Score says

ANTX scores -2 today, which Breakaway calls Poor. It is #166 of 291 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 28% in 3 months, 30% under its 50-⁠day average. Cash lasts about 10 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is ANTX's Quality Score?

ANTX scores -2 today, which Breakaway calls Poor (below zero). That is #166 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ANTX's -2.

Are insiders buying ANTX?

One insider sold $25K across 1 filing in the last 6 months. No open-⁠market buys on record. The newest is Joshua M. Eizen, Insider, who sold $25K on Jul 8.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.